Merola, J., Sofen, H., Thaci, D., Paul, C., Imafuku, S., Banerjee, .S. and Armstrong , A. 2021. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s36. DOI:https://doi.org/10.25251/skin.5.supp.36.